Molecular Monitoring of NPM1 is a Useful Tool for Detecting Early-Stage Relapse and to Guide Pre-Emptive Treatment Approaches in Patients with NPM1-Mutated Acute Myeloid Leukemia

Molecular monitoring of minimal residual disease (MRD) in Acute Myeloid Leukemia (AML) patients (pts) with mutated NPM1 (NPM1+) is a prognostic tool, not only for predicting disease relapse but also for its potential role to guide pre-emptive therapy in early-stage relapse (Ivey 2016). The utility of MRD detection by multiparameter flow-cytometry (MFC) in the setting of AML pts with a molecular marker is still unclear. We evaluated the prognostic significance of molecular and MFC MRD monitoring on pts outcome and the efficacy of relapse treatment in AML NPM1+ pts at a single Institution.